Healthcare Professionals
Prophylaxis in children
Patient information
You can download the following files in PDF format :
Summary of Product Characteristics Prescribing Information Patient Information Leaflet
Objective
A multi-centre, open-label, two-arm, prospective, randomised clinical trial to compare full prophylaxis with an on-demand treatment regimen for joint haemorrhage 23
Study criteria
Sixty-five boys with haemophilia A aged between 6 and 30 months from 15 haemophilia centres were enrolled 23
The boys were randomised to receive a regimen of alternate day infusions of KOGENATE® Bayer at 25iu/kg to prevent haemorrhage or an on demand therapy regimen using ≥3 infusions totalling ≥80iu/kg KOGENATE® Bayer at the time of each joint haemorrhage 23
Outcomes
The study showed that prophylaxis patients had fewer joint bleeds per year compared to ‘on-demand' patients
MRI analysis at aged 6 years
Joint bleeds per year
JOINT OUTCOME STUDY
Landmark Study Demonstrates Benefits of Early Prophylactic Use of Recombinant Factor VIII
References
23. Manco-Johnson MJ et al. N Engl J Med 2007;357:535-544
Produced by Bayer. This website is intended for HealthCare professionals.
Date of preparation: December 2010
UK.PH.HN.KOG.2010.250.29.3